Bariatric Surgery Candidate, Diabetes type2
Conditions
Brief summary
This study seeks to examine the impact of bariatric surgery on oral bacteria in diabetic compared to non-diabetic patients. The purpose of this research study is to examine how diabetes changes the bacteria in the mouth. This is an important question since bacterial changes may impact oral health. Participants will attend a screening and baseline visit prior to bariatric surgery and three post bariatric surgery appointments (3 weeks post, 6 months post and 1 year to 18 months post). Samples collected at each study visit include blood, plaque, and other oral samples. At the last study visit there is an optional dental cleaning.
Interventions
OTHERsample collection
Blood, plaque, and other oral samples
Sponsors
University of Pennsylvania
National Institute of Dental and Craniofacial Research (NIDCR)
Temple University
Ohio State University
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
25 Years to 65 Years
Inclusion criteria
* Men and women undergoing bariatric surgery who are 25-65 years old. * BMI \> 35 kg/m2. * Diabetic subjects: HbA1c\> 6.0% or fasting plasma glucose \>126 mg/dl). * Normoglycemic subjects: HbA1c\<5.75% or fasting plasma glucose \<100 mg/dl). * Dental criteria: Minimum of 4 posterior teeth. * Signed and dated informed consent form. * Willing to comply with all study procedures and be available for the duration of the study.
Exclusion criteria
* Subjects diagnosed with type 1 diabetes, maturity onset diabetes of the young (MODY), or latent autoimmune diabetes in adults (LADA). * Women who are considering pregnancy or are currently breastfeeding. * Individuals with a history of chronic inflammatory or autoimmune diseases or taking medications that affect immune function or affect body weight such as chronic systemic steroids. * Currently smoke more than 10 cigarettes per day. * Periodontal treatment within 3 months of bacterial sampling. * Acute periodontal infection (abscess) within 1 month of bacterial sampling or abscess in teeth or adjacent teeth within 1 month of sampling. * Treatment with antibiotics within one month of sample collection (except as part of the surgical regimen of prophylactic antibiotic immediately prior to surgery). * A treatment regimen of steroids within 1 month of sample collection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bacterial composition | 18 months | as determined by 16s rRNA community profiling |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bacterial mRNA profiling | 18 months | RNA will be isolated then amplified by the MessageAmp II bacterial RNA amplification kit (Ambion/Life Technologies). Ribosomal RNA will be depleted with the RiboZero human/mouse and meta bacterial kits (Epicentre/Illumina) and human mRNA will be depleted with oligo(dT). Illumina sequencing libraries will be constructed with the Illumina TruSeq RNA kit and assessed with an Illumina HiSeq instrument. |
| Gingival inflammation | 18 mos. | samples will be assessed for inflammatory cytokines (e.g. IL-1β, IL-17 or TNF) by multiplex assay or ELISA assay |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORDana Graves, DDS, DMSc
University of Pennsylvania
Outcome results
None listed